Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.

The human epidermal growth factor receptor (EGFR) is an important therapeutic target in patients with metastatic colorectal cancer and anti-EGFR antibodies cetuximab and panitumumab have been approved for the treatment of such patients. Despite these advances, the duration of response in some patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan Michael Seddon, Helmout Modjtahedi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a68cd94d6394432e95ced38128f944e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a68cd94d6394432e95ced38128f944e1
record_format	dspace
spelling	oai:doaj.org-article:a68cd94d6394432e95ced38128f944e12021-11-18T08:29:05ZCo-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.1932-620310.1371/journal.pone.0091139https://doaj.org/article/a68cd94d6394432e95ced38128f944e12014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24609222/?tool=EBIhttps://doaj.org/toc/1932-6203The human epidermal growth factor receptor (EGFR) is an important therapeutic target in patients with metastatic colorectal cancer and anti-EGFR antibodies cetuximab and panitumumab have been approved for the treatment of such patients. Despite these advances, the duration of response in some patients can be limited. Since, EGFR is capable of forming heterodimers with the other members of the HER (Human epidermal receptor) family, it is important to investigate the co-expression and prognostic significance of all members of the HER family in colorectal cancer patients. The expression of the HER family members were determined in tumour specimens from 86 patients with Dukes' C and D (metastatic) colon cancer using immunohistochemistry. Sections were scored by the percentage of positive tumour cells and intensity of staining. Their associations with clinicopathological parameters, and overall survival and disease free survival were evaluated using univariate and multivariate analysis. Overall, 43%, 77%, 52% and 92% of the cases were EGFR, HER-2, HER-3 and HER-4 positive respectively. Interestingly, 35%, 24%, 43%, and 18% of the cases had co-expression of EGFR/HER-2, EGFR/HER-3, EGFR/HER-4 and all four members of the HER family respectively. Of these, only the expression of EGFR and co-expression of EGFR/HER-4 were associated with poorer disease-free survival in both univariate and multivariate analysis. Co-expression of all members of the HER family in colon cancer supports the need for further investigations on their predictive value for response to therapy with anti-EGFR mAbs and whether such sub-population of patients may benefit from therapy with the new generation of pan-HER inhibitors.Said Abdullah KhelwattySharadah EssapenIzhar BagwanMargaret GreenAlan Michael SeddonHelmout ModjtahediPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e91139 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Said Abdullah Khelwatty Sharadah Essapen Izhar Bagwan Margaret Green Alan Michael Seddon Helmout Modjtahedi Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
description	The human epidermal growth factor receptor (EGFR) is an important therapeutic target in patients with metastatic colorectal cancer and anti-EGFR antibodies cetuximab and panitumumab have been approved for the treatment of such patients. Despite these advances, the duration of response in some patients can be limited. Since, EGFR is capable of forming heterodimers with the other members of the HER (Human epidermal receptor) family, it is important to investigate the co-expression and prognostic significance of all members of the HER family in colorectal cancer patients. The expression of the HER family members were determined in tumour specimens from 86 patients with Dukes' C and D (metastatic) colon cancer using immunohistochemistry. Sections were scored by the percentage of positive tumour cells and intensity of staining. Their associations with clinicopathological parameters, and overall survival and disease free survival were evaluated using univariate and multivariate analysis. Overall, 43%, 77%, 52% and 92% of the cases were EGFR, HER-2, HER-3 and HER-4 positive respectively. Interestingly, 35%, 24%, 43%, and 18% of the cases had co-expression of EGFR/HER-2, EGFR/HER-3, EGFR/HER-4 and all four members of the HER family respectively. Of these, only the expression of EGFR and co-expression of EGFR/HER-4 were associated with poorer disease-free survival in both univariate and multivariate analysis. Co-expression of all members of the HER family in colon cancer supports the need for further investigations on their predictive value for response to therapy with anti-EGFR mAbs and whether such sub-population of patients may benefit from therapy with the new generation of pan-HER inhibitors.
format	article
author	Said Abdullah Khelwatty Sharadah Essapen Izhar Bagwan Margaret Green Alan Michael Seddon Helmout Modjtahedi
author_facet	Said Abdullah Khelwatty Sharadah Essapen Izhar Bagwan Margaret Green Alan Michael Seddon Helmout Modjtahedi
author_sort	Said Abdullah Khelwatty
title	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
title_short	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
title_full	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
title_fullStr	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
title_full_unstemmed	Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
title_sort	co-expression of her family members in patients with dukes' c and d colon cancer and their impacts on patient prognosis and survival.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/a68cd94d6394432e95ced38128f944e1
work_keys_str_mv	AT saidabdullahkhelwatty coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival AT sharadahessapen coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival AT izharbagwan coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival AT margaretgreen coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival AT alanmichaelseddon coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival AT helmoutmodjtahedi coexpressionofherfamilymembersinpatientswithdukescanddcoloncancerandtheirimpactsonpatientprognosisandsurvival
_version_	1718421759838912512

Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.

Ejemplares similares